Pfizer gets into stem cell research

In recent years, research based on embryonic stem cells has led to a great deal of controversy. However, increasingly, researchers are finding techniques that may allow them to turn average cells into cells with the characteristics of embryonic stem cells, something that could theoretically offer the benefits of stem cell research without the controversy. Now, drugmaker Pfizer has announced that it's getting into this game, opening a "regenerative medicine unit" in Cambridge, MA that will attempt to use these techniques. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.